Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Simcere Zaiming Pharmaceutical Co. Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SIM-0508, a small-molecule inhibitor of DNA polymerase θ (POLθ), allowing initiation of clinical trials in locally advanced or metastatic solid tumors.
China’s National Medical Products Administration authorized the country’s first cetuximab biosimilar with the approval of Simcere Zaiming’s Enlituo (CMAB-009, cetuximab beta injection) in combination with chemotherapy as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer. The biosimilar references originator drug Erbitux (cetuximab, Eli Lilly and Co.).
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or bromodomain-containing protein 4 (BRD4; HUNK1) targeting moiety through a linker reported to be useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized tricyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized antibody-drug conjugates (ADC) comprising humanized monoclonal antibodies targeting CDH6 covalently linked to a camptothecin analogue through a linker.
Simcere Pharmaceutical Group Ltd.’s subsidiary Simcere Zaiming Pharmaceutical Co. Ltd. has received FDA clearance of an IND application for SIM-0501, an oral small-molecule inhibitor of ubiquitin-specific peptidase 1 (USP1), for advanced solid tumors.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of respiratory tract infections.
